University of Texas's MD Anderson and Obsidian Therapeutics Announce FDA Clearance of IND Application for Novel TIL Therapy OBX-115
July 22, 2022
July 22, 2022
HOUSTON, Texas, July 22 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
FDA granted IND clearance for OBX-115, Obsidian's lead engineered TIL therapy, for the treatment of patients with solid tumors
* * *
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (I . . .
* * *
FDA granted IND clearance for OBX-115, Obsidian's lead engineered TIL therapy, for the treatment of patients with solid tumors
* * *
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (I . . .